KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Depreciation and Depletion (2016 - 2025)

CRISPR Therapeutics AG's Depreciation and Depletion history spans 11 years, with the latest figure at $5.7 million for Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 18.75% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $19.4 million, up 1.04%, while the annual FY2025 figure was $19.4 million, 1.04% up from the prior year.
  • Depreciation and Depletion for Q4 2025 was $5.7 million at CRISPR Therapeutics AG, up from $4.4 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $7.3 million in Q2 2022 and bottomed at $2.7 million in Q1 2021.
  • The 5-year median for Depreciation and Depletion is $4.9 million (2023), against an average of $5.0 million.
  • The largest annual shift saw Depreciation and Depletion soared 148.0% in 2021 before it plummeted 31.51% in 2023.
  • A 5-year view of Depreciation and Depletion shows it stood at $6.2 million in 2021, then fell by 6.45% to $5.8 million in 2022, then fell by 15.52% to $4.9 million in 2023, then decreased by 2.04% to $4.8 million in 2024, then increased by 18.75% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Depreciation and Depletion are $5.7 million (Q4 2025), $4.4 million (Q3 2025), and $4.6 million (Q2 2025).